KALA BIO, INC. Debt Securities, Available-for-sale, Unrealized Loss
KALA BIO, INC. (KALA) reported Debt Securities, Available-for-sale, Unrealized Loss of $4.00 thousand for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2020-11-05
- KALA BIO, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2020-09-30 was -$13.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month |
|---|---|---|---|
| 2020-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $4.00K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $17.00K 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |